GeneDx Holdings Corp. - Class A Common Stock (WGS)
52.21
-4.06 (-7.22%)
NASDAQ· Last Trade: Jun 6th, 7:25 PM EDT
Detailed Quote
Previous Close
56.27
Open
56.27
Bid
51.00
Ask
52.00
Day's Range
51.84 - 56.29
52 Week Range
32.21 - 170.87
Volume
1,182,414
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,653,103
Chart
About GeneDx Holdings Corp. - Class A Common Stock (WGS)
GeneDx Holdings Corp. is a genomics company that specializes in providing genetic testing services to aid in the diagnosis and treatment of various genetic disorders. By leveraging advanced genomic technologies and bioinformatics, the company aims to deliver accurate and comprehensive genetic information that helps clinicians make informed decisions about patient care. GeneDx focuses on enhancing the understanding of rare and hereditary diseases, facilitating personalized medicine, and improving patient outcomes through insightful genomic data services. Read More
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026. GeneDx describes itself as an “American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing and whole exome sequencing for the diagnosis of rare and inherited disorders.”
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. (“GeneDx” or “the Company”) (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing services for diagnosing pediatric and rare diseases.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10 in Miami, FL. Management will participate in a fireside chat on Tuesday, June 9, 2026, at 8:00 a.m. ET.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GeneDx (WGS) To Contact Him Directly To Discuss Their Options
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GeneDx (WGS) To Contact Him Directly To Discuss Their Options
The law firm of Kirby McInerney LLP is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of investors concerning the Company’s possible violations of federal securities laws.
